{
    "nctId": "NCT03122301",
    "briefTitle": "Effects of Stellate Ganglion Block on Hot Flashes in Hispanic Women With Breast Cancer",
    "officialTitle": "Effects of Stellate Ganglion Block on Hot Flashes in Hispanic Women With Breast Cancer: A Pilot Randomized Sham-Controlled Trial",
    "overallStatus": "TERMINATED",
    "conditions": "Hot Flashes, Hot Flushes, Vasomotor Symptoms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 2,
    "primaryOutcomeMeasure": "2 Month Subject Reported Daily Hot Flashes (Mean)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Hispanic or Spanish speaking women aged 30 to 70 years\n2. 28 or more reported moderate-to-very severe hot flashes per week\n3. a minimum of two weeks of VMS diary recording prior to SGB\n4. current use of tamoxifen, aromatase inhibitors, or SERMs for a breast cancer indication for at last six months\n5. willingness to undergo fluoroscopy-guided SGB or sham treatment.\n6. if participant is on an SSRI,SNRI or membrane stabilizer (pregabalin, gabapentin, for example), it must be a stable, unchanged dose for previous 3 months\n\nExclusion Criteria:\n\n1. conditions that preclude SGB or sham intervention (e.g., anatomic abnormalities of the anterior neck or cervical spine; goiter, cardiac/pulmonary compromise; acute illness/infection; coagulopathy or bleeding disorder; allergic reactions/contraindications to a local anesthetic or contrast dye); pregnancy 2. use of treatments in the past 2 months that can affect VMS (e.g., use of oral or transdermal HT or contraceptives,\n\n-",
    "sex": "FEMALE",
    "minimumAge": "30 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}